Viewing Study NCT04221542



Ignite Creation Date: 2024-05-06 @ 2:08 PM
Last Modification Date: 2024-10-26 @ 1:25 PM
Study NCT ID: NCT04221542
Status: RECRUITING
Last Update Posted: 2024-06-13
First Post: 2019-12-16

Brief Title: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Amgen
Organization: Amgen

Study Overview

Official Title: A Phase 1 Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose MTD or recommended phase 2 dose RP2D
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2023-504361-23 OTHER EU CT Number None
2021-005052-11 EUDRACT_NUMBER None None